NCBiotech News

As algae blooms fed by chemical fertilizer runoff from farms and lawns contaminate more waterways every year, Mirimichi Green Express is rooting its future in high-end eco-sensitive plant-growing products in the Southeastern North Carolina community of Castle Hayne, near Wilmington.

Durham-based 410 Medical, developer of a new medical device for treating critically ill patients, has raised $3.1 million in new financing to commercialize the product.

A simple idea became a life-changing one for a young Duke physician assistant who never planned to do anything but practice medicine. Now Shawn Gage is not only an inventor, but an entrepreneur too.

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company based in Durham, has reported positive clinical results for Rhopressa, its once-daily eye drop approved for the reduction of elevated eye pressure, a cause of glaucoma.

Hernan Navarro, Ph.D., retired chief scientist for RTI International’s Center for Drug Discovery, has returned to the workplace to direct the Biomedical Research Institute and Technology Enterprise (BRITE) at North Carolina Central University in Durham. 

Raleigh-based Eva Garland Consulting (EGC) is on the prestigious Inc. 5000 list of the country’s fastest-growing private companies.

North Carolina is home to six of the top 10 community colleges in the nation, according to SmartAsset, an online site aimed at helping people make smart financial decisions.

Funding from the North Carolina Biotechnology Center has enabled doctors in Western N.C. to use genetic testing to prescribe more-effective medicines for their patients. It’s part of a larger center-led effort to promote the statewide growth and development of precision health.

BARDA's Division of Research, Innovation and Ventures, or DRIVe, has simplified the process companies and researchers can use to apply for grants to fund disruptive solutions to health security threats.

When URO-1 Medical of Winston-Salem needed help commercializing its new medical device, the startup tapped a neighbor: Novex Innovations, a contract development and manufacturing organization that helps life science companies get their products to market quickly and inexpensively. 

Just three weeks after scuttling plans to merge with a Pennsylvania company and move there, publicly traded Durham biotechnology company BioCryst Pharmaceuticals is selling up to $57.5 million in stock in an underwritten public offering.

BASF, a German conglomerate with global reach in chemical, pharmaceutical and agricultural science, has closed its huge $9 billion purchase of businesses and assets from Bayer, moving four facilities and more than 360 former Bayer employees into the fold of BASF’s Research Triangle Park operations.

The U.S. Food and Drug Administration has approved for sale Baytril Soft Chewable Tablets, the third pet medicine OK’d for Bayer based on the soft-chew platform invented by Piedmont Animal Health in Greensboro.

United Therapeutics Corp. has received approval from the U.S. Food and Drug Administration to begin marketing and selling an implantable system for delivering Remodulin, its treatment for pulmonary arterial hypertension (PAH), or high blood pressure in the lungs.

The North Carolina Biotechnology Center awarded 11 grants and loans totaling $2,125,000 to universities, bioscience companies and other organizations in the fourth quarter of fiscal year 2018 ending June 30.